Matinas BioPharma (NYSEAMERICAN:MTNB) Receives “Hold” Rating from Maxim Group

Maxim Group reiterated their hold rating on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a report issued on Thursday, Benzinga reports.

Matinas BioPharma Stock Performance

NYSEAMERICAN MTNB opened at $0.62 on Thursday. Matinas BioPharma has a 12-month low of $0.54 and a 12-month high of $21.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02).

Hedge Funds Weigh In On Matinas BioPharma

A number of hedge funds have recently bought and sold shares of MTNB. Towercrest Capital Management bought a new stake in shares of Matinas BioPharma during the 2nd quarter worth $299,000. Alliance Wealth Management Group bought a new stake in shares of Matinas BioPharma during the 2nd quarter worth $299,000. Finally, Highbridge Capital Management LLC bought a new stake in shares of Matinas BioPharma during the 2nd quarter worth $1,685,000. 11.77% of the stock is owned by hedge funds and other institutional investors.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.